Sign up for free insights newsletter
Johnson & Johnson

Johnson & Johnson

JNJUnited States

Need professional-grade analysis? Visit stockanalysis.com

$235.37
-0.80%
End of day
Market Cap

$582.04B

P/E Ratio

21.88

Employees

138,200

Dividend Yield

2.12%

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino7.649.013.640.954.82
Calmar13.4715.134.040.587.30
Sharpe4.315.022.440.642.85
Omega1.901.971.481.131.57
Martin51.2240.5311.771.2422.40
Ulcer1.401.984.038.694.45

Johnson & Johnson (JNJ) Price Performance

Johnson & Johnson (JNJ) trades on United States in USD. The company is classified in the Healthcare sector under the Drug Manufacturers - General industry. The stock currently trades at $235.37, down 0.80% from the previous close.

Over the past year, JNJ has traded between a low of $143.15 and a high of $248.56. The stock has gained 49.4% over this period. It is currently 5.3% below its 52-week high.

Johnson & Johnson has a market capitalization of $582.04B, with a price-to-earnings ratio of 21.88 and a dividend yield of 2.12%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Company Info

Exchange
United States
Currency
USD

Financial Metrics

Revenue (TTM)
$85.16B
EBITDA
$33.84B
Profit Margin
28.46%
EPS (TTM)
11.04
Book Value
33.87

Technical Indicators

52 Week High
$251.71
52 Week Low
$138.40
50 Day MA
$230.93
200 Day MA
$192.48
Beta
0.33

Valuation

Trailing P/E
21.88
Forward P/E
20.92
Price/Sales
6.18
Price/Book
7.14
Enterprise Value
$658.96B